Medivir AB
Lunastigen 7
Huddinge
141 44
Tel: 46-8-608-3100
Fax: 46-8-608-3199
Website: http://www.medivir.se/
Email: medivir@medivir.se
487 articles about Medivir AB
-
Medivir to present at Swiss Nordic Bio in Zürich on March 7
3/6/2024
Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.
-
Medivir to present at the Life Science Day in Gothenburg on March 6
3/4/2024
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Life Science Day in Gothenburg on March 6, 2024.
-
Change in Medivir's nomination committee before the 2024 AGM
2/26/2024
Medivir AB announces that that the nomination committee before the annual general meeting in May 2024 changes as follows.
-
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit
2/22/2024
Medivir AB announced that clinical pharmacokinetic data on dose linearity and systemic exposure from the first study with fostroxacitabine bralpamide will be presented at the European Association for the Study of the Liver Liver Cancer Summit on February 23, 2024, in Rotterdam.
-
Medivir AB - Year-End Report January - December 2023
2/15/2024
The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months.
-
Number of shares and votes in Medivir AB on 31 January 2024
1/31/2024
Medivir AB announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024.
-
Medivir announces the outcome of the directed share issue which was announced on 22 January 2024
1/26/2024
7,547,170 shares were issued, and all shares have been subscribed for by and allotted to Hallberg Management AB in accordance with the resolution regarding the share issue.
-
Medivir to present at the Redeye Fight Cancer Day - January 24, 2024
1/24/2024
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, January 24, 2024.
-
Medivir carries out a directed share issue of approx. SEK 20 million
1/23/2024
Medivir AB announced that the board of directors of MedivirAB, as authorised by the general meeting on 4 May 2023, has resolved on a directed issue of 7,547,170 new ordinary shares through which the Company receives approx.
-
Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)
1/23/2024
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, invites to a conference call on the updated data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma.
-
Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium
1/17/2024
Medivir AB announced further improved clinical benefit with fostrox + Lenvima® as data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma will be presented at the ASCO GI Symposium in San Francisco on January 19.
-
Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox
1/15/2024
Medivir AB announced that clinical pharmacokinetic data from the first study with fostroxacitabine bralpamide will be presented at the European Association for the Study of the Liver Liver Cancer Summit in February 22-24, 2024 in Rotterdam.
-
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
1/4/2024
Medivir AB announced that Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor.
-
Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan
12/19/2023
Medivir AB announced improved durable clinical benefit in maturing data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma, measured by local review.
-
Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval
12/13/2023
Medivir AB announced that it has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug substance for the planned phase 2b to enable study drug availability end of 2024 and ensure maximum momentum in the fostrox development program.
-
Medivir to present at the Carlsquare Equity Research Investor Day - December 06, 2023
12/6/2023
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.
-
Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway
12/6/2023
Medivir AB announced that its partner, IGM Biosciences, has communicated a strategic pipeline prioritization and reduction of workforce with the key aim of extending its cash runway in a challenging financial climate.
-
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
11/27/2023
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that it has finalized the development of an updated formulation of fostrox, suitable for commercial manufacture.
-
Medivir to present at the Redeye Life Science Day - November 22, 2023
11/22/2023
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.
-
Medivir to present at the Erik Penser Bank Company Event - November 21, 2023
11/21/2023
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.